Background: The REPRISE Japan study, a prospective multicenter single-arm trial, was undertaken to confirm the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with the LOTUS valve in Japanese subjects with severe symptomatic calcific aortic stenosis at extreme or high surgical risk.
Methods and results: REPRISE Japan enrolled 40 subjects in the transfemoral (TF) cohort (mean age 84 years; mean [±SD] Society of Thoracic Surgeons [STS] score 6.4±2.9%); 10 additional subjects were treated with a transaortic (TAo) approach (mean age 84 years; mean STS score 6.3±3.3%). A subanalysis was also performed on subjects treated with the 21-mm LOTUS valve (n=15; mean age 84 years; mean STS score 5.3±2.1%). The primary safety endpoint (a composite of all-cause mortality, stroke, life-threatening or major bleeding events, acute kidney injury [Stage 2/3], and major vascular complications at 30 days) occurred in 15% of TF subjects. The primary effectiveness endpoint (a composite of all-cause mortality, disabling stroke, and moderate or greater paravalvular leak [PVL; core laboratory assessed] at 6 months) occurred in 5.3% of TF subjects. Across the TF, TAo, and 21-mm LOTUS valve cohorts, no subjects exhibited moderate or greater PVL at 6 months. The 30-day rate of pacemaker implantation was 22.5% in the TF cohort (TAo: 20%; 21 mm: 13.3%).
Conclusions: Data from REPRISE Japan confirm the safety and efficacy of the LOTUS Valve when used in Japanese clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1253/circj.CJ-20-0064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes in Patients Treated With a Repositionable and Fully Retrievable Aortic Valve - REPRISE Japan Study.
Circ J
June 2021
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine.
Background: The REPRISE Japan study, a prospective multicenter single-arm trial, was undertaken to confirm the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with the LOTUS valve in Japanese subjects with severe symptomatic calcific aortic stenosis at extreme or high surgical risk.
Methods and results: REPRISE Japan enrolled 40 subjects in the transfemoral (TF) cohort (mean age 84 years; mean [±SD] Society of Thoracic Surgeons [STS] score 6.4±2.
Postpartal resumption of ovarian activity in dairy cows: Implications for herbage-based feeding systems in Switzerland.
Schweiz Arch Tierheilkd
November 2020
Veterinary Physiology, Vetsuisse Faculty, University of Bern, Switzerland.
Milk production in Switzerland is mainly based on herbage feeding with little input of concentrates. The present study investigated the effects of a solely herbage-based diet with (C) and without concentrate (nC) supplementation on luteal activity, milk production and metabolic status in 23 multiparous Holstein dairy cows with early or delayed resumption of ovarian cyclicity post partum (pp). Cows were retrospectively assigned either to a group with early (until d 25 pp, EOV) or delayed resumption of ovarian activity (> d 30 pp, DOV), resulting in four subgroups depending on concentrate feeding: DOV-C, DOV-nC, EOV-C, EOV-nC.
View Article and Find Full Text PDFTolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Drugs
February 2019
Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Tolvaptan [Jynarque (USA); Jinarc (EU, Canada); Samsca (Japan)] is a highly selective vasopressin V receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). In the phase III TEMPO 3:4 trial, 3 years' treatment with tolvaptan slowed the increase in total kidney volume (TKV) and the decline in renal function relative to placebo. The composite secondary endpoint of time to investigator-assessed clinical progression also favoured tolvaptan over placebo.
View Article and Find Full Text PDFVitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.
Cell
September 2014
Gene Expression Laboratory, Salk Institute, La Jolla, CA 92037, USA; Howard Hughes Medical Institute, Salk Institute, La Jolla, CA 92037, USA. Electronic address:
The poor clinical outcome in pancreatic ductal adenocarcinoma (PDA) is attributed to intrinsic chemoresistance and a growth-permissive tumor microenvironment. Conversion of quiescent to activated pancreatic stellate cells (PSCs) drives the severe stromal reaction that characterizes PDA. Here, we reveal that the vitamin D receptor (VDR) is expressed in stroma from human pancreatic tumors and that treatment with the VDR ligand calcipotriol markedly reduced markers of inflammation and fibrosis in pancreatitis and human tumor stroma.
View Article and Find Full Text PDFRevisiting "how many steps are enough?".
Med Sci Sports Exerc
July 2008
Walking Behavior Laboratory, Pennington Biomedical Research Center, Baton Rogue, LA 70808, USA.
With continued widespread acceptance of pedometers by both researchers and practitioners, evidence-based steps/day indices are needed to facilitate measurement and motivation applications of physical activity (PA) in public health. Therefore, the purpose of this article is to reprise, update, and extend the current understanding of dose-response relationships in terms of pedometer-determined PA. Any pedometer-based PA guideline presumes an accurate and standardized measure of steps; at this time, industry standards establishing quality control of instrumentation is limited to Japan where public health pedometer applications and the 10,000 steps.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!